Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection

Lancet

Volumn 348, Issue 9041, 1996, Pages 1547-1551

  Eron Jr , Joseph J ^a   Ashby, Mark A ^b   Giordano, Michael F ^c   Chernow, Marlene ^b   Reiter, William M ^d   Deeks, Steven G ^e   Lavelle, James P ^f   Conant, Marcus A ^g   Yangco, Bienvenido G ^h   Pate, Perry G ⁱ   Torres, Ramón A ^j   Mitsuyasu, Ronald T ^k   Twaddell, Thomas ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b GENENTECH INC   (United States)

^c Cornell Medical Center ^*  (United States)

^d Center for Special Immunology   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g Conant Medical Group ^*  (United States)

^h Infectious Disease Research Institute   (United States)

ⁱ Dallas ID Associates   (United States)

^j ST VINCENT S HOSPITAL   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS TITRATION;

EID: 10544220020     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)05283-X     Document Type: Article

References (9)

1. Moore JP, Cao Y, Ho DD, Koup RA. Development of the anti-gp 120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994; 68: 5142-55.
2. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Viral 1994; 68: 4650-55.
3. Fernandez CE, Desco M, Garcia MM, Longo N, Gonzalez B, Zabay JM. Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected drug users. Aids 1990; 4: 987-94.
4. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-79.
5. Sinicco A, Fora R, Sciandra M, Lucchini A, Caramello P, Gioannini P. Risk of developing AIDS after primary acute HIV-1 infection. J Acquir Immune Defic Syndr 1993; 6: 575-81.
6. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209-16.
7. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332: 201-08.
8. Cavacini LA, Ernes CL, Power J, et al. Loss of serum antibodies to a conformational epitope of HIV-1/gp 120 idenified by a human monoclonal antibody is associated with disease progression. J Acquir Immune Defic Syndr 1993; 6: 1093-102.
9. Wolinsky S, Korber B, Neumann A, et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996; 272: 537-42.